I'm LongbridgeAI, I can summarize articles.Kardigan, Inc. reported a net loss of $116.2M and diluted EPS of $(4.61) for Q2 2026, widening from the prior year's loss. The company recorded no revenue as it invests in late-stage clinical programs for danicamtiv, ataciguat, and tonlamarsen, with topline data expected in H1 2027. Operational costs rose due to R&D scale-up and M&A integration efforts.
Kardigan, Inc. reported a net loss of $116.2M for the second quarter of 2026 and diluted loss per share of $(4.61). The company recorded no revenue for the three- or six-month periods ended June 30, 2026, as it continues to invest heavily in late-stage clinical programs and platform integration.
Financial Highlights
- Revenue: No revenue reported for the three- or six-month periods ended June 30, 2026 or 2025.
- Net income: Net loss $116.2M for 2Q 2026, compared with net loss $57.4M in 2Q 2025 (approximately a $58.8M increase in loss year over year).
- Diluted EPS: Net loss per share, basic and diluted $(4.61) for 2Q 2026, versus $(4.64) in 2Q 2025.
Business Highlights
- Clinical program progress: Advanced three late-stage programs—danicamtiv, ataciguat and tonlamarsen—with ongoing Phase trials and topline data expected in H1 2027.
- Operational scale-up: Increased R&D activity, headcount growth and greater use of external CROs/CMOs have driven higher program spending during the quarter.
- Platform and M&A integration: Continued integration of the Prolaio platform with amended milestones; the platform is being used for trial patient management and analytics.
- Commercial positioning: Management is preparing commercialization planning for targeted precision cardiovascular indications and pursuing clear regulatory pathways pending trial outcomes and approvals.
Original SEC Filing: Kardigan, Inc. [ KARD ] - 10-Q - Aug. 11, 2026